Pemphigoid after immune checkpoint inhibitors and other antineoplastic medications: a Danish nationwide case–control study
Clinical and Experimental Dermatology · 2026-10-07
DOI: 10.1093/ced/llag426 ↗Abstract
Abstract Background Immune checkpoint inhibitors have been linked to an increased risk of incident pemphigoid. Objectives To examine the association between immune checkpoint inhibitor treatment and incident pemphigoid using nationwide data in Denmark, including comparison with other antineoplastic medications. Methods This was a nationwide matched case–control study in Denmark of cases with incident pemphigoid identified through Danish national registries between 2019 and 2024. Cases were matched 1 : 100 with population controls on age, sex and index date. Exposure was defined as at least one recorded hospital administration of an immune checkpoint inhibitor within 3 months before the index date. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using conditional logistic regression. In additional analyses, we examined molecularly targeted therapy and conventional chemotherapy using the same exposure window. Results We identified 951 cases of pemphigoid and 95 100 controls. Among cases, 7 (0.74%) had been treated with an immune checkpoint inhibitor, compared with 64 controls (0.07%; OR 11.1, 95% CI 5.04–24.2). In an additional analysis, 5 cases (0.53%) had been treated with molecularly targeted therapy and 6 cases (0.63%) had been treated with conventional chemotherapy, compared with 262 (0.28%; OR 1.91, 95% CI 0.79–4.65) and 250 (0.26%; OR 2.42, 95% CI 1.07–5.45) controls, respectively. After adjusting for these other antineoplastic medications, the association between immune checkpoint inhibitor exposure and pemphigoid remained statistically significant (OR 10.4, 95% CI 4.72–22.9). Conclusions Immune checkpoint inhibitor treatment was associated with a substantially increased risk of incident pemphigoid in this Danish nationwide case–control study.
EUVIMED